ORIGINALCONTRIBUTION
Effect of Continuous Positive Airway
Scan for Author
Video Interview
Pressure on the Incidence of Hypertension
and Cardiovascular Events in Nonsleepy Patients
With Obstructive Sleep Apnea
A Randomized Controlled Trial
FerranBarbe´, MD
Context Continuouspositiveairwaypressure(CPAP)isthefirst-linetreatmentforpa-
Joaquı´nDura´n-Cantolla, MD tientswithsymptomaticobstructivesleepapnea(OSA).However,itsindicationforall
patientswithsleep-disorderedbreathing,regardlessofdaytimesymptoms,isunclear.
ManuelSa´nchez-de-la-Torre, PhD
Objective ToevaluatetheeffectofCPAPtreatmentontheincidenceofhyperten-
Montserrat
sionorcardiovasculareventsinacohortofnonsleepypatientswithOSA.
Martı´nez-Alonso, BSc(Stat)
Design, Setting, and Patients Multicenter, parallel-group, randomized con-
CarmenCarmona, MD
trolledtrialin14teachinghospitalsinSpain.BetweenMay2004andMay2006,725
AntoniaBarcelo´, MD consecutivepatientswereenrolledwhohadanapnea-hypopneaindexof20h−1or
EusebiChiner, MD greaterandanEpworthSleepinessScalescoreof10orless(scoresrangefrom0-24,
withvalues(cid:2)10suggestingnodaytimesleepiness).Exclusioncriteriawereprevious
JuanF.Masa, MD
cardiovascularevent,physicalorpsychologicalincapacity,chronicdisease,ordrugor
Mo´nicaGonzalez, MD alcoholaddiction.Follow-upendedinMay2009.
JoseM.Marı´n, MD Intervention PatientswereallocatedtoreceiveCPAPtreatmentornoactiveinter-
vention.Allparticipantsreceiveddietarycounselingandsleephygieneadvice.
FranciscoGarcia-Rio, MD
MainOutcomeMeasures Incidenceofeithersystemichypertension(takingan-
JosefaDiazdeAtauri, MD
tihypertensivemedicationorbloodpressuregreaterthan140/90mmHg)orcardio-
Joaquı´nTera´n, MD vascularevent(nonfatalmyocardialinfarction,nonfatalstroke,transientischemicattack,
MercedesMayos, MD hospitalizationforunstableanginaorarrhythmia,heartfailure,orcardiovasculardeath).
MónicadelaPen˜a, MD Results Sevenhundredtwenty-threepatientsunderwentfollow-upforamedianof4
(interquartilerange,2.7-4.4)years(1patientfromeachgroupdidnotreceiveallocated
CarmenMonasterio, MD
treatment);357intheCPAPgroupand366inthecontrolgroupwereincludedinthe
FelixdelCampo, MD analysis.IntheCPAPgrouptherewere68patientswithnewhypertensionand28car-
diovascularevents(17unstableanginaorarrhythmia,3nonfatalstroke,3heartfailure,
JosepM.Montserrat, MD
2nonfatalmyocardialinfarction,2transientischemicattack,1cardiovasculardeath).In
fortheSpanishSleepandBreathing thecontrolgrouptherewere79patientswithnewhypertensionand31cardiovascular
Network events(11unstableanginaorarrhythmia,8nonfatalmyocardialinfarction,5transient
ischemicattack,5heartfailure,2nonfatalstroke).Thehypertensionorcardiovascular
O BSTRUCTIVE SLEEP APNEA eventincidencedensityratewas9.20per100person-years(95%CI,7.36-11.04)in
(OSA) is a common dis- theCPAPgroupand11.02per100person-years(95%CI,8.96-13.08)inthecontrol
easethataffects3%to7%of group.Theincidencedensityratiowas0.83(95%CI,0.63-1.1;P=.20).
the general population.1,2 Conclusions InpatientswithOSAwithoutdaytimesleepiness,theprescriptionof
Sleepapneaiscausedbythecollapseof CPAPcomparedwithusualcaredidnotresultinastatisticallysignificantreductionin
the upper airway during sleep, which theincidenceofhypertensionorcardiovascularevents.However,thestudymayhave
hadlimitedpowertodetectasignificantdifference.
leadstotransientasphyxia.Theseevents
lead to brain arousal, intermittent hy- TrialRegistration clinicaltrials.govIdentifier:NCT00127348
poxemia(whichinduceshypersomno- JAMA.2012;307(20):2161-2168 www.jama.com
AuthorAffiliationsandaListoftheMembersofthe
lence), poor quality of life, and meta- SpanishSleepandBreathingNetworkappearatthe
Seealsopp2169and2197. endofthisarticle.
bolicdisturbances.Cross-sectionaland CorrespondingAuthor:FerranBarbe´,MD,Respira-
AuthorVideoInterviewavailableat longitudinalstudieshaveshownanas- toryDepartment,IRBLleida,HospitalUniversitariAr-
www.jama.com. naudeVilanova,RoviraRoure,80,25198Lleida,Spain
sociation between OSA and hyperten- (fbarbe@arnau.scs.es).
©2012AmericanMedicalAssociation.Allrightsreserved. JAMA,May23/30,2012—Vol307,No.20 2161
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
sion,3,4andOSAhasbeenassociatedwith 2009. Patients were referred to sleep velopes.Thecoordinatingcentersaved
cardiovasculardiseases,5-7althoughthis units for evaluation of observed ap- asealedcopyoftherandomizationlist
associationisattenuatedinsomestud- neas or snoring. The study was ap- senttoeachcenter.Bloodpressuresand
ieswhenadjustedforageandobesity.8 provedbytheethicscommitteeofeach all cardiovascular events were as-
Continuouspositiveairwaypressure participatingcenter,andpatientspro- sessedobjectivelybypersonnelnotin-
(CPAP)actsasapneumaticsplinttothe videdwritteninformedconsent. volvedinthestudyandblindedtopa-
upperairwayduringsleepandcorrects Patientswereeligibleiftheywerebe- tientallocation.Patients,researchers,
the obstruction, improving daytime tween18and70yearsold,showed20 andthestatisticianwerenotblindedto
sleepinessandqualityoflifeinpatients or more apneas plus hypopneas per patientallocation.
withOSA.9Also,CPAPtreatmentcanre- hour(apnea-hypopneaindex[AHI])in CPAPtitrationwasperformedusing
ducebloodpressureinthesepatients.10 an overnight sleep study, and had no conventionalpolysomnographyoran
ObservationalstudiessuggestthatCPAP daytimehypersomnolence,definedas autoCPAP device following a vali-
treatmentreducestheincidenceoffatal anEpworthSleepinessScale(ESS)score datedprotocol.17CPAPadherencewas
andnonfatalcardiovasculareventsinpa- of10orlower(ESSscoreshavearange measured using the machines’ inter-
tientswithsevere11andmoderate12OSA. of 0-24). The exclusion criteria were nal clocks. All participants received
However,noneofthesestudieswereran- physical or psychological incapacity, sleephygieneadviceanddietarycoun-
domized. To perform such studies in any previous cardiovascular event, selingforweightlossfromthestaffof
symptomaticpatientswouldbeunethi- chronicdisease,drugoralcoholaddic- thesleepunits.Therewasnospecific
calbecauseavailableevidenceoftheef- tion,chronicintakeofhypnotics,orre- weightlossprogram,andpatientswere
fectivenessofCPAPonsymptomcon- fusal to participate in the study. Pa- referredtotheirgeneralpractitionerto
trol and accident risk precludes the tients with a history of hypertension monitorweightloss.
possibilityofwithholdingtreatmentin werenotexcluded.
a long-term study. The indication for TheOSAdiagnosiswasmadeusing OutcomesandFollow-up
CPAPtreatmentinnonsleepypatientsis a conventional polysomnographic or The primary outcome was the inci-
underdebate.Twoshort-termrandom- cardiorespiratorysleepstudy.Thecar- denceofeithersystemichypertension
izedcontrolledtrialshaveshownnoef- diorespiratorystudyincluded,atmini- (amongparticipantswhowerenormo-
fectofCPAPonbloodpressureandclini- mum,continuousrecordingfromna- tensive at baseline) or cardiovascular
calvariablesinnonsleepypatientswith sal cannulae, thoracic-abdominal events (among all participants). The
OSA.13,14 Nonetheless, because of the motion, oxygen saturation, and body secondary outcome was the associa-
highincidenceofcardiovascularcom- position.Resultsfromallsleepstudies tion between the incidence of hyper-
plicationsinpatientswithOSA,someau- wereanalyzedbytrainedpersonnelat tensionorcardiovasculareventsandthe
thors advocate the long-term use of each participating center, using stan- severityofOSAassessedbytheAHIand
CPAP treatment for all patients with dardcriteria.Anapneawasdefinedas oxygensaturation.
sleep-disorderedbreathing,regardlessof anabsenceofairflowof10secondsor Informationregardingmedicationuse,
daytimesymptoms.15 longerandahypopneaasanairflowre- OSA severity, sleepiness (ESS score),
The primary objective of this study duction((cid:3)50%)lasting10secondsor bloodpressure,abasicbiochemicalas-
wastoevaluatetheeffectofCPAPtreat- longer with a greater than 4% de- sessment,andresultsofelectrocardiog-
mentontheincidenceofhypertension creaseinoxygensaturation.Obstruc- raphywererecordedforeachpatientat
orcardiovasculareventsinacohortof tive apneas were defined as the ab- inclusion. Cardiovascular events in-
nonsleepypatientswithOSA.Westud- senceofairflowinthepresenceofchest cludednonfatalmyocardialinfarction,
iedthiscompositeoutcomebecausehy- orabdominalwallmotion.TheAHIwas nonfatalstroke,transientischemicattack,
pertension and cardiovascular events calculatedbasedontheaveragenum- hospitalizationforunstableanginaorar-
have been associated with OSA, they ber of apnea plus hypopnea episodes rhythmia,heartfailure,andcardiovas-
sharerelatedpathologicalpathways,and perhourofsleeporrecordingtime. cular death. All cardiovascular events
theirclinicalrelevancehasbeenestab- wereidentifiedbyacardiologistorneu-
lished.16Thesecondaryobjectivewasto Randomization,Blinding, rologistnotinvolvedinthestudyand
evaluatetherelationshipbetweenOSA andIntervention blindedtothepatients’randomization
severityandtheincidenceofhyperten- Eligible patients were randomly as- status.Hypertensionwasdefinedastak-
sionorcardiovascularevents. signed in a 1:1 ratio to receive CPAP ingantihypertensivemedicationorblood
treatment or no active intervention. pressure greater than 140/90 mm Hg.
METHODS
Randomizationwasperformedusinga Bloodpressuremeasurementsweretaken
SettingandParticipants computer-generated list of random byexperiencednurses,followinginter-
Recruitmenttookplacein14Spanish numbersinthecoordinatingcenterand nationalguidelines.18
teachinghospitalsbetweenMay2004 was stratified by center. The results Patientswereevaluatedat3,6,and
andMay2006.Follow-upendedinMay weremailedinnumberedopaqueen- 12monthsandannuallythereafter.The
2162 JAMA,May23/30,2012—Vol307,No.20 ©2012AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
study was designed to follow up pa- low-upvisits,takingintoaccountthe ences between hospitals in quantita-
tientsforatleast3years.However,fol- timebetweenvisitsandthelastavail- tivebaselinevariables.
low-up for the main outcome was ableinformation. Thesecondaryoutcomeofthestudy
stopped when the patients developed Mann-Whitneytests(orttestsifdata wastoassesstheassociationbetween
new-onset hypertension or experi- were normally distributed) and Pear- theincidenceofcardiovascularevents
enced a cardiovascular event, with- son(cid:6)2testswithaYatescontinuitycor- orhypertensionanddiseaseseverity.To
drewinformedconsent,wereunableto rection (or Fisher exact tests if ex- assessthisassociation,wetestedthein-
completefollow-up,orwhentherewas pected frequencies were less than 5) teractionofseverityvariables(AHIand
achangefromcontrolgrouptoCPAP wereusedforcontinuousandcategori- time with arterial oxygen saturation
treatment.Exposuretimewasdefined calvariables,respectively,whencom- [SaO2] (cid:2)90%, dichotomized into 2
asthetimebetweenrandomizationand paring the CPAP and control groups. groupsbasedontheirmedianvalues)
first cardiovascular event or new- TheeffectoftheCPAPinterventionwas withtheinterventioninaPoissonre-
onsethypertension,dateofdeath,date assessedasanincidencedensityratio gressionmodel,withtheoutcomevari-
of the last study visit, date of with- (IDR)ofhypertensionorcardiovascu- ablebeingtheincidenceofhyperten-
drawal,orlosstofollow-up. lar events, and significance was as- sionorcardiovascularevents.
Ateachvisitaphysicianrecordedcar- sessed using the Wald test. A modi- Differences between baseline val-
diovascularevents,bloodpressure,ESS fied intention-to-treat approach was uesandthemeanareaunderthecurve
score,weight,CPAPadherence,medi- used,inwhichallpatientsreceivingthe forBMIandESSscoreinfollow-upvis-
cations,alcoholandtobaccoconsump- allocatedinterventionwereincludedin its were calculated for each patient.
tion,andotherclinicallyrelevantevents. theanalysisoftheprimaryoutcome. These differences were compared be-
Formodelingincidence,aPoissonre- tween intervention groups using the
SampleSize gressionmodelwasusedandadjusted Mann-Whitneynonparametrictest.
Thesamplesizewascalculatedassum- for intervention group. An additional
RESULTS
ingthattheincidenceofhypertensionor analysisincludingrandomhospital(site)
newcardiovasculareventinthispopu- effectwasperformedbecauseofthehos- A total of 725 patients were random-
lationoveraperiodof3yearswouldbe pitalimbalancesinbaselinevariables.A ized,with357intheCPAPgroupand
10%annually.Thisestimationwasbased goodness-of-fittestfortheassumption 366 in the control group analyzed
on published studies19 and data pro- of a Poisson distribution was per- (FIGURE 1). Baseline variables were
videdbytheSpanishNationalEpidemi- formedineveryadjustedmodeltode- comparablebetweentheCPAPandcon-
ologyCenter.WeestimatedthatCPAP termine if a negative binomial model trolgroups,withtheexceptionofAHI
wouldreducetheincidenceofnewhy- shouldbeusedinstead.TheuseofaCox andtimewithSaO2lessthan90%.Fifty
pertensionorcardiovasculareventsby proportionalhazardsregressionmodel percent of the sample was hyperten-
60%basedonacohortstudybyMarin wasnotpossiblebecausethedatadidnot siveatinclusion(TABLE1).Manyofthe
etal11thatshowedacardiovascularevent satisfytheproportionalhazardsassump- baselinevariableshadsite-specificdif-
rateof2.13per100person-yearsinan tion.20Availableinformationwasused ferences (eTable 1, available at http:
untreatedgroupvs0.64per100person- withnoneedforimputation. //www.jama.com).
yearsinagroupofpatientstreatedwith Thecumulativeincidence,CI(t),of Follow-uptimeuntilacardiovascu-
CPAP,a70%relativeratereduction.We eventsattimetwasestimatedusingthe larevent,losstofollow-up,ortheend
assumed(cid:4)=.05,(cid:5)=.10,2-sidedsignifi- incidencedensityatthattime,ID(t),in ofthestudyrangedfrom0to5.38years,
cancetesting,and10%studydropout. theequationCI(t)=1−exp{−ID(t)*t}. withamedianof4.0years(interquar-
Under these assumptions, the study Therefore, each point of the graph tilerange[IQR],2.7-4.4years).There
wouldneedtoenrollatotalof345pa- shows the cumulative incidence after werenosignificantdifferencesinme-
tientspergroup. t years of follow-up in the study, ex- dianfollow-upbetweengroupsusing
pressed as a percentage. A post hoc the Mann-Whitney test (4.01 years
StatisticalAnalysis analysiswasperformedtoassessapos- [IQR, 3.01-4.37] for the CPAP group
Datawerestoredinaweb-basedappli- sible dose-response relationship. For vs3.96years[IQR,2.19-4.38]forthe
cation. R version 2.10.1 was used for thisanalysis,theCPAPgroupwaspar- controlgroup;P=.13).
allanalyses.Estimatedmeansfortreat- titioned based on whether the mean
mentadherence,bodymassindex(BMI, CPAPadherenceduringfollow-upwas PrimaryOutcome:EffectsofCPAP
calculated as weight in kilograms di- less than 4 hours.11 The outcomes in ontheIncidenceofHypertension
videdbyheightinmeterssquared),and each of these CPAP subgroups were orCardiovascularEvents
ESS scores during the follow-up pe- compared with those in the control Atotalof147patientswithnewhyper-
riod were computed individually for group. The Kruskal-Wallis rank-sum tension and 59 cardiovascular events
eachpatientastheareaunderthecurve test was used to analyze the dose- wereidentified.IntheCPAPgroup,there
obtainedfromthevaluesreportedinfol- responserelationshipaswellasdiffer- were 68 patients with new hyperten-
©2012AmericanMedicalAssociation.Allrightsreserved. JAMA,May23/30,2012—Vol307,No.20 2163
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
PrimaryOutcome
Figure1.ParticipantFlow
byAdherenceSubgroups
PatientswhousedCPAPforlessthan4
983Patients assessed for eligibility
h/nighthadanIDRof1.13(95%CI,0.78-
1.64;P=.51),comparedwiththecontrol
258Excluded
111Did not meet inclusion criteria group. In contrast, patients who used
53Cardiovascular antecedents
37Previously diagnosed chronic CPAPfor4h/nightorlongerhadanIDR
illness
18Other sleep disorder of 0.72 (95% CI. 0.52-0.98; P=.04)
3Addiction or alcoholism (Table2andFigure2B).Adjustmentfor
60Declined to participate
87Other randomhospital(site)effectdidnotsub-
stantiallymodifytheseresults(Table3).
725Randomized
SecondaryOutcome
358Randomized to receive CPAP 367Randomized to receive no active intervention byAdherenceSubgroups
357Received CPAP as randomized 366Received no active intervention InposthocanalysestheeffectofCPAP
1Did not receive CPAP as randomized
(previous cardiovascular event) 1Did not receive randomized intervention ontheincidenceofhypertensionorcar-
(previous cardiovascular event)
diovasculareventswithreferencetothe
controlgroupshowedasignificantinter-
59Lost to follow-up 66Lost to follow-up
44Early dropout during follow-up 58Early dropout during follow-up actionwithtimewithSaO2lessthan90%
15Early dropout (no follow-up) 8Early dropout (no follow-up)
whenCPAPwaspartitionedbasedona
3Discontinued intervention (drug use, 17Discontinued intervention (somnolence,
surgery, other) change to CPAP, hypertension, other) thresholdof4hoursofadherence(P=.03),
whileinteractionwithAHIremainednon-
357Included in primary analysis 366Included in primary analysis significant(P=.57).Thus,theeffectof
CPAPwassignificantlydifferentwhentak-
Onlythosepatientsexcludedintheallocationprocesswereexcludedfromtheanalysis.Discontinuationof
interventionwasmorefrequentinthecontrolgroup,inwhichpatientswereexcludedbecauseofsomnolence ingintoaccountadherence,depending
(n=7),changetocontinuouspositiveairwaypressure(CPAP)(n=5),hypertension(n=2),drugabuse(n=1), onwhetherthevalueofthepercentage
pregnancy(n=1),orothercause(n=1).
oftimewithSaO2lessthan90%wasgreater
thantheoverallmedianof6.8%.
sionand28cardiovascularevents(17 effectofCPAPontheincidenceofhy- Anotherstratifiedanalysiswascon-
hospitalizationsforunstableanginaorar- pertension or cardiovascular events ducted,adjustingforAHI.Thesamplewas
rhythmia,3nonfatalstroke,3heartfail- with reference to the control group firstdividedintosubgroupsbasedonthe
ure,2nonfatalmyocardialinfarction,2 showednosignificantdifferencesacross percentageoftimewithSaO2lessthan90%
transientischemicattack,1cardiovas- subgroupsofAHI(P=.48)ortheper- (withacutpointof6.8%ofthetime).
culardeath).Inthecontrolgroup,there centageoftimewithSaO2lessthan90% Thesesubgroupswerethendividedagain
were 79 patients with new hyperten- (P=.23).Nosignificantinteractionwas basedonCPAPadherence(withacut-
sionand31cardiovascularevents(11 found between treatment group and pointof4h/night).For6.8%oftimeor
hospitalizationsforunstableanginaorar- eachofthediseaseseverityvariables. lesswithSaO2lessthan90%,theIDRwas
rhythmia,8nonfatalmyocardialinfarc- 0.71(95%CI,0.40-1.27;P=.25)forCPAP
tion,5transientischemicattack,5heart SubgroupAnalyses adherencelessthan4h/nightand0.72
failure, 2 nonfatal stroke). The inci- ThemeanCPAPadherencerangedfrom (95%CI,0.45-1.15;P=.17)forCPAPad-
dencedensityrateforhypertensionor 0to8.76h/night,withamedianof5.00 herenceof4h/nightorlonger.Forgreater
cardiovasculareventsintheCPAPgroup h/night(IQR,2.18-6.25).Inaposthoc than6.8%oftimewithSaO2lessthan90%,
was11.02per100person-yearsandin analysis,wepartitionedthepatientsin theIDRwas1.89(95%CI,1.14-3.13;
thecontrolgroupwas9.20per100per- theCPAPgroupbasedonameanad- P=.01)forCPAPadherencelessthan4
son-years.TheIDRwas0.83(95%CI, herenceof4h/night.11Therewere127 h/night and 0.71 (95% CI, 0.45-1.13;
0.63-1.1; P=.20) (TABLE 2 and patients (36%) with a mean adher- P=.15)forCPAPadherenceof4h/night
FIGURE 2A). Adjustment for random encelessthan4h/night(median,1.00 orlonger.Thus,IDRdifferedsignificantly
hospital (site) effect did not substan- [IQR,0.00-2.75])and230withadher- fromthecontrolgrouponlyinthesub-
tiallymodifytheseresults(TABLE3) enceof4h/nightorlonger(median,5.96 groupwithgreaterthan6.8%oftimewith
[IQR,5.05-6.70]).Thereweresignifi- SaO2lessthan90%andCPAPadherence
SecondaryOutcomes:Relationship cant differences between these sub- lessthan4h/night.
BetweenIncidenceofEvents groupsinAHI,timewithSaO2lessthan
andOSASeverity 90%,neckcircumference,BMI,andhy- AdditionalResults
DiseaseseveritywasassessedusingAHI pertension when compared at base- Theseparateincidenceofcardiovascu-
andtimewithSaO2lessthan90%.The line(TABLE4). lar events or new-onset hypertension
2164 JAMA,May23/30,2012—Vol307,No.20 ©2012AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
is reported in the supplementary on- creasedincidenceofhypertension,car- effectofCPAPtherapyonbloodpres-
line content. When assessed sepa- diovascular events, or sudden death sure in patients with OSA. Results
rately,CPAPdidnotshowanystatis- duringsleep.4,6,7,21Threesystematicre- showedsignificantbloodpressurere-
ticallysignificanteffectontheincidence views,22-244meta-analysesincluding21 ductions, especially in patients with
ofnewcardiovascularevents(eTable2, randomizedcontrolledtrials,10,25-27and more severe OSA.25,26 However, evi-
eTable 3, and eFigure 1) or on new- 3recentstudies28-30haveevaluatedthe denceforaneffectofCPAPtreatment
onset hypertension (eTable 4, eTable
5,andeFigure2).
There were 8 deaths in the CPAP Table1.PatientCharacteristicsatBaseline
groupand3inthecontrolgroup.The Control CPAP P
IDRfordeathwas2.6(95%CI,0.70- Characteristic (n=366) (n=357) Valuea
11.8;P=.16).Ofthepatientsassigned Age,mean(SD),y 51.8(11.01) 52.0(10.90) .75b
toCPAP,5diedofcancer,1ofcardio- Men,No.(%) 306(83.6) 313(87.7) .12
vascular causes, 1 of trauma, and an- Bodymassindex,mean(SD)c 31.1(4.98) 31.3(4.86) .45b
otherofunknowncauses.Amongcon- Neckcircumference,mean(SD),cm 42.0(3.70) 42.4(3.64) .19
trols,thecausesofdeathwerecancer Currentsmoking,No.(%) 94(25.7) 113(31.7) .09
for2andunknownfor1. Anyalcoholuse,No.(%) 129(46.7) 131(48.3) .77
DecreasesinBMIweresignificantly Bloodpressure,mean(SD),mmHg
Systolic 130.9(16.89) 131.6(16.56) .58b
greaterinthecontrolgroupthaninthe
Diastolic 79.9(11.46) 80.0(11.41) .99b
CPAPgroup,withasignificantdiffer-
Hypertension,No.(%) 183(50.0) 190(53.2) .43
enceof0.25(95%CI,0.04-0.46;P=.02)
Anyantihypertensivedrugs,No.(%) 82(22.4) 95(26.6) .22
(eTable6).Bothgroupshadchangesin
ACEinhibitors,No.(%) 48(13.1) 48(13.4) .98
ESSscores,butthesechangesweresig-
AngiotensinIIreceptorblockers,No.(%) 8(2.2) 11(3.1) .60
nificantlylessinthecontrolgroupthan
Calciumchannelblockers,No.(%) 11(3.0) 19(5.3) .17
in the CPAP group (0.2 vs 1.3; (cid:5)-Blockers,No.(%) 17(4.6) 21(5.9) .56
P(cid:2).001),withasignificantdifference
Diuretics,No.(%) 29(7.9) 30(8.4) .92
of−1.1(95%CI,−1.4to−0.7;P(cid:2).001)
(cid:7)1Antihypertensivedrugtreatment,No.(%) 26(7.1) 30(8.4) .61
(eTable7). EpworthSleepinessScalescore 6.5(2.24) 6.5(2.27) .95b
Apnea-hypopneaindex,median(IQR),h−1 35(26-49) 42(29-59) (cid:2).001d
COMMENT
TimewithSaO2(cid:2)90%,median(IQR),% 6(1.6-15.0) 8(2.0-22.8) .04d
Thisstudysuggeststhatinpatientswith Diagnosisbypolysomnography,No.(%) 186(50.8) 198(55.5) .24
OSAandwithoutdaytimesleepiness,the Glucose,median(IQR),mg/dL 97(90-109) 98(90-108) .80d
prescription of CPAP compared with Lipids,mg/dL
usual care did not result in a statisti- Totalcholesterol,mean(SD) 213.0(41.78) 212.6(43.28) .89b
cally significant reduction in the inci- Triglycerides,median(IQR) 116.5(84.3-169.0) 122.5(86.3-175.0) .26d
denceofhypertensionorcardiovascu- Alteredelectrocardiogram,No.(%) 20(5.5) 20(5.6%) .93
lar events. However, a larger study or Abbreviations:ACE,angiotensin-convertingenzyme;CPAP,continuouspositiveairwaypressure;IQR,interquartilerange;
SaO2,arterialoxygensaturation.
longerfollow-upmighthavebeenable SIconversionfactors:Toconvertglucosevaluestommol/L,multiplyby0.0555;totalcholesterolvaluestommol/L,multiply
by0.0259;triglyceridesvaluestommol/L,multiplyby0.0113.
toidentifyasignificantassociationbe- aPearson(cid:6)2testPvalueexceptasnoted.
tween treatment and outcome. A post
bFromttest.
cCalculatedasweightinkilogramsdividedbyheightinmeterssquared.
hocanalysissuggestedthatCPAPtreat- dFromMann-Whitneytest.
mentmayreducetheincidenceofhy-
pertensionorcardiovasculareventsinpa-
Table2.RiskforNewHypertensionorCardiovascularEvent
tientswithCPAPadherenceof4h/night
Intention-to-TreatAnalysis AnalysisbyAdherencetoCPAPUse
orlonger.Thediseaseseverityassessed
bytheAHIandtimewithSaO2lessthan Control CPAP CPAP(cid:2)4h/Night CPAP(cid:7)4h/Night
(n=366) (n=357) (n=127) (n=230)
90%wasnotrelatedtotheincidenceof
Events 110 96 37 59
hypertensionorcardiovascularevents.
Person-years 997.837 1043.436 296.4271 747.0089
However, patients with worse oxygen
Eventsper100 11.02(8.96-13.08) 9.20(7.36-11.04) 12.48(8.46-16.50) 7.90(5.88-9.91)
saturationatnightandwithCPAPad-
person-years
herenceoflessthan4h/nightshoweda (95%CI)
higher rate of hypertension or cardio- IDR(95%CI) 1[Reference] 0.83(0.63-1.10) 1.13(0.78-1.64) 0.72(0.52-0.98)
vasculareventsthanthecontrolgroup. Pvaluea .20 .51 .04
Compellingevidenceindicatesthat Abbreviations:CPAP,continuouspositiveairwaypressure;IDR,incidencedensityratio.
aFromWaldtest.
severe OSA is associated with an in-
©2012AmericanMedicalAssociation.Allrightsreserved. JAMA,May23/30,2012—Vol307,No.20 2165
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
Figure2.CumulativeIncidenceofHypertensionorCardiovascularEventsDuringFollow-up
A
50
Control
40 CPAP
30
20
10
0
0 1 2 3 4 5 6
Years of Follow-up
No. at risk
Control 366 264 234 206 134 10
CPAP 357 271 247 217 148 16
nonsleepypatientshaveshownnoef-
Table3.PoissonRegressionPredictingHypertensionorCardiovascularEvents,WithHospital
fectofCPAPonclinicalsymptomsor
asaRandomEffect,Intention-to-TreatAnalysis
blood pressure,13,14 and a long-term
AdjustedIDR P Variance,
(95%CI) Value RandomHospitalEffect study showed a mild beneficial effect
CPAPvscontrolgroup 0.81(0.61-1.06) .13 0.1141 ofCPAPonbloodpressureonlyinpa-
CPAPadherencesubgroupanalysis tientswhousedCPAPfor5.6h/night
CPAP(cid:2)4h/nightgroup 1.12(0.77-1.64) .55 0.1183 or longer.28 In our study, the protec-
vscontrolgroup
tiveassociationofCPAPusewiththe
CPAP(cid:7)4h/nightgroup 0.69(0.50-0.94) .02
vscontrolgroup incidence of hypertension or cardio-
Abbreviations:CPAP,continuouspositiveairwaypressure;IDR,incidencedensityratio. vasculareventsinthesubgroupofpa-
tients with adherence of 4 h/night or
longerwasseendespitethatsubgroup
oncardiovasculareventsislessdefini- inthegeneralpopulationorinnonap- beingmoreobeseandhavingahigher
tive. Peker et al31 reported a signifi- neic snorers. Overall, observational prevalenceofhypertension.However,
cant increase in the incidence of car- studies suggest a protective effect of theresultsofposthocanalysesshould
diovasculardiseaseamongincompletely CPAP treatment on cardiovascular be interpreted with caution and con-
treatedpatientswithOSAcomparedto eventsinpatientswithOSA. sideredhypothesisgenerating.Inthese
thosewhowereefficientlytreated.Sev- Inaposthocanalysisinourstudy, analyses, patients were not random-
eralauthors11,12,32,33havereportedanim- CPAPwaseffectiveinpatientswhoused izedtothesubgroups,andfindingsmay
provementinlong-termsurvivalasso- thetreatmentformorethan4h/night. haveresultedfromaconfoundingbias,
ciated with treatment in different Eveninthesepatients,themagnitude suchasthehealthy-usereffect(eg,ad-
cohortsofpatientswithOSA.Marinet oftheeffectwaslessthaninprevious herentCPAPusersmaybemorelikely
al11followedupamalecohortoftreated observationalstudies.11Inthestudyby to be adherent with other medica-
anduntreatedpatientswithOSA,snor- Marin et al,11 the group treated with tions,treatments,exercise,nutrition,or
ers,andthegeneralpopulationfor10 CPAPhadaneventrateof0.64per100 otherhealthmaintenance).
yearsinanobservationalstudy.They person-years,whereastheeventratein It has been postulated that non-
showed that CPAP treatment was as- ourtreatmentgroupwas2.08per100 sleepypatientstreatedwithCPAPwill
sociatedwithalowerriskoffataland person-years(eTable2).Theseresults probablyhavepooradherence.Ourre-
nonfatal cardiovascular events in pa- arenotunexpected,becauserandom- sultsdonotsupportthisstatementand
tients with severe OSA when com- izedtrialsoftenshowsmallerpositive show that CPAP treatment is feasible
paredwithpatientswhorefusedCPAP effectsthanobservationalstudies. in this population, even in the ab-
treatment.Theincidenceofcardiovas- Anotherpossibleexplanationisthat senceofanyspecificreinforcement.An
culareventsinpatientsreceivingCPAP CPAPislesseffectiveinnonsleepypa- unexpectedfindingwastherelatively
treatmentwasnotdifferentfromthat tients.Short-termstudiesfocusingon highnumberofdeathsduringfollow-
%
,ecnedicnI
evitalumuC
B
50 CPAP <4 h/night
Control
40
CPAP ≥4 h/night
P = .20
30
20
10
0
0 1 2 3 4 5 6
Years of Follow-up
No. at risk
Control 366 264 234 206 134 10
CPAP <4 h/night 127 79 72 56 41 3
CPAP ≥4 h/night 230 192 175 161 107 13
%
,ecnedicnI
evitalumuC
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
P = .51
P = .04
A,Cumulativeincidenceofhypertensionorcardiovasculareventsfortheinterventiongroupsduringfollow-upandthePvaluefortheincidencedensityratioofcon-
tinuouspositiveairwaypressure(CPAP)vscontrol(Waldtest).B,PanelAwithCPAPgroupstratifiedaccordingtoadherence((cid:2)4vs(cid:7)4h/night)andthePvaluesfor
theirincidencedensityratiosinreferencetothecontrolgroup.
2166 JAMA,May23/30,2012—Vol307,No.20 ©2012AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
up.Thestudysamplesizewasnotlarge
Table4.ComparisonofSubgroupsofCPAPAdherenceatBaseline
enoughtoreachaconclusionaboutany
CPAP(cid:2)4h/Night CPAP(cid:7)4h/Night P
relationship to treatment, but this is- (n=127) (n=230) Valuea
suedeservesfurtherresearch.
Age,mean(SD),y 51.9(10.16) 52.1(11.31) .85
The strengths of our study include
Men,No.(%) 112(88.2) 201(87.4) .96
itsmulticentricdesignandthegener- Bodymassindex,mean(SD)b 30.4(4.85) 31.8(4.81) .009
alizability of the trial findings. Base- Neckcircumference,mean(SD),cm 41.7(3.59) 42.8(3.62) .01
linecardiovascularriskfactorswerenot Currentsmoking,No.(%) 42(33.1) 71(30.9) .76
differentbetweengroups,andmedian Anyalcoholuse,No.(%) 43(47.3) 88(48.9) .90
follow-uptimewassimilar.Neverthe- Bloodpressure,mean(SD),mmHg
less, this study has several potential Systolic 129.3(16.84) 132.9(16.30) .053
limitations. Diastolic 78.6(11.86) 80.7(11.11) .11
First, the lack of effect of CPAP Hypertension,No.(%) 58(45.7) 132(57.4) .04
on hypertension or cardiovascular Anyantihypertensivedrugs,No.(%) 28(22.0) 67(29.1) .19
events could be related to an inad- ACEinhibitors,mean(SD) 17(13.4) 31(13.5) .89
equately powered estimation of the AngiotensinIIreceptorblockers,No.(%) 6(4.7) 5(2.2) .31
sample size. The lack of previous Calciumchannelblockers,No.(%) 4(3.1) 15(6.5) .27
(cid:5)-Blockers,No.(%) 4(3.1) 17(7.4) .16
studiessuitableforsamplesizecalcu-
Diuretics,No.(%) 8(6.3) 22(9.6) .39
lation contributed to the difficulty of
(cid:7)1Antihypertensivedrugtreatment,No.(%) 9(7.1) 21(9.1) .64
sample size estimation. The potential
EpworthSleepinessScalescore 6.6(2.18) 6.5(2.33) .74
protective effect of CPAP was prob-
Apnea-hypopneaindex,median(IQR),h−1 33(27-53) 47(33-63) (cid:2).001c
ably overestimated, and a larger
studyorlongerfollow-upmighthave
TimewithSaO2(cid:2)90%,median(IQR) 5(1.1-15.0) 10(2.2-27.0) .005c
Diagnosisbypolysomnography,No.(%) 74(58.3) 124(53.9) .50
been able to identify a significant
Glucose,median(IQR),mg/dL 99(91-105) 98(90-110) .97c
association between treatment and
Lipids,mg/dL
outcome. Including patients with Totalcholesterol,mean(SD) 216.2(46.63) 210.6(41.38) .28
hypertension also might have con- Triglycerides,median(IQR) 117(84.0-177.3) 125(87.0-171.3) .40c
tributed to a lack of study power, Alteredelectrocardiogram,No.(%) 4(3.1) 16(7.0) .21
because these patients could not AutomaticCPAPtitration,No.(%) 101(79.5) 178(77.4) .74
develop 1 component of the com- CPAPpressure,median(IQR),cmHO 8(7-9) 9(7-10) .07c
2
bined primary end point, incident Abbreviations:ACE,angiotensin-convertingenzyme;CPAP,continuouspositiveairwaypressure;IQR,interquartilerange;
hypertension. Incident hypertension SaO2,arterialoxygensaturation.
SIconversionfactors:Toconvertglucosevaluestommol/L,multiplyby0.0555;totalcholesterolvaluestommol/L,multiply
accounted for more than two-thirds by0.0259;triglyceridesvaluestommol/L,multiplyby0.0113.
aFromttestexceptasnoted.
of the primary end point events. bCalculatedasweightinkilogramsdividedbyheightinmeterssquared.
Second, medical research personnel
cFromMann-Whitneytest
were not blinded to patient alloca-
tion. However, cardiovascular events inaccuracyoftheexaminer’sausculta- incidence of hypertension or cardio-
and blood pressure were assessed tion technique. However, measure- vascular events. However, the study
objectively, by personnel not in- ments were taken by experienced mayhavehadlimitedpowertodetect
volved in the study and blinded to nurses following international guide- a significant difference. A post hoc
patientallocation. lines.Fifth,onepossibleexplanationfor analysis suggested that CPAP treat-
Third, at baseline the CPAP group thesmallereffectsizeofCPAPinthis mentmayreducetheincidenceofhy-
had higher AHI scores and slightly trialcomparedwithpriorstudiesisthat pertensionorcardiovasculareventsin
greatertimewithSaO2lessthan90%. thetitrationprotocolsmayhavebeen patients with CPAP adherence of 4
These differences, although statisti- less effective, resulting in an elevated h/nightorlonger.
cally significant, were likely to be of residual AHI on CPAP treatment. Al-
little clinical relevance, because both though we do not know if this oc- AuthorAffiliations:CoordinatorCentre,IRBLleida,
Lleida(DrsBarbe´ andSa´nchez-de-la-TorreandMr
groupshadsevereOSA,andallother curred,ourCPAPtitrationprotocolhas Martı´nez-Alonso);HospitalUniversitariodeÁlava,Vi-
characteristicsandcardiovascularrisk beenvalidatedinpreviousstudiesper- toria(DrDura´n-Cantolla);HospitalVirgendelRocı´o,
Sevilla(DrCarmona);HospitalUnivSonDureta,Palma
factorsweresimilarbetweenthegroups formedbyourresearchgroup.17
deMallorca(DrsBarcelo´anddelaPen˜a);HospitalSant
atbaseline.Fourth,bloodpressureval- In conclusion, in this study of pa- Joan,Alacant(DrChiner);HospitalSanPedrodeAl-
ca´ntaraHospital,Ca´ceres(DrMasa);HospitalMar-
ues were measured at clinic visits, an tientswithOSAwithoutdaytimesleepi-
quésdeValdecilla,Santander(DrGonzalez);Hospi-
approach that can be affected by the ness, the prescription of CPAP com- talMiguelServet,Zaragoza(DrMarı´n);Hospital
white coat effect, observer bias, lim- paredwithusualcaredidnotresultin UniversitarioLaPaz-IdiPAZ,Madrid(DrGarcia-Rio);
Hospital12deOctubre,Madrid(DrDiazdeAtauri);
ited reproducibility, and the intrinsic astatisticallysignificantreductioninthe HospitalGeneralYagu¨e,Burgos(DrTera´n);Hospital
©2012AmericanMedicalAssociation.Allrightsreserved. JAMA,May23/30,2012—Vol307,No.20 2167
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
CPAPANDHYPERTENSIONANDCARDIOVASCULAREVENTS
SantPau,Barcelona(DrMayos);HospitaldeBell- REFERENCES sure:alargemulticenterstudy.AmJRespirCritCare
vitge,Barcelona(DrMonasterio);HospitalRioHortega, Med.2004;170(11):1218-1224.
Valladolid(DrdelCampo);HospitalClinic,Barcelona 1. Dura´nJ,EsnaolaS,RubioR,IztuetaA.Obstruc- 18. ChobanianAV,BakrisGL,BlackHR,etal;Joint
(DrMontserratandHerna´ndez);CIBERes,Madrid(Drs tivesleepapnea-hypopneaandrelatedclinicalfea- NationalCommitteeonPrevention,Detection,Evalu-
Barbe´,Dura´n-Cantolla,Sa´nchez-de-la-Torre,Barcelo´, turesinapopulation-basedsampleofsubjectsaged ation,andTreatmentofHighBloodPressure;Na-
Masa,Marı´n,Tera´n,Mayos,delaPen˜a,Monasterio, 30to70yr.AmJRespirCritCareMed.2001; tionalHeart,Lung,andBloodInstitute;NationalHigh
andMontserrat),Spain. 163(3,pt1):685-689. BloodPressureEducationProgramCoordinating
AuthorContributions:DrBarbe´hadfullaccesstoall 2. PunjabiNM.Theepidemiologyofadultobstruc- Committee.SeventhreportoftheJointNationalCom-
ofthedatainthestudyandtakesresponsibilityfor tive sleep apnea. Proc Am Thorac Soc. 2008;5 mitteeonPrevention,Detection,Evaluation,andTreat-
theintegrityofthedataandtheaccuracyofthedata (2):136-143. mentofHighBloodPressure.Hypertension.2003;
analysis. 3. NietoFJ,YoungTB,LindBK,etal;SleepHeartHealth 42(6):1206-1252.
Studyconceptanddesign:Barbe´,Dura´n-Cantolla, Study.Associationofsleep-disorderedbreathing, 19. RutledgeT,LindenW.Defensivenessstatuspre-
Chiner,Masa,Marı´n,Garcı´a-Rı´o,Dı´az-De-Atauri, sleepapnea,andhypertensioninalargecommunity- dicts3-yearincidenceofhypertension.JHypertens.
Mayos,Monasterio,delCampo,Montserrat. basedstudy.JAMA.2000;283(14):1829-1836. 2000;18(2):153-159.
Acquisitionofdata:Barbe´,Dura´n-Cantolla,Sa´nchez- 4. PeppardPE,YoungT,PaltaM,SkatrudJ.Prospec- 20. TherneauTM,GrambschPM.Proportionalhaz-
de-la-Torre,Carmona,Chiner,Masa,Gonzalez, tive study of the association between sleep- ardstestsanddiagnosticsbasedonweightedresiduals.
Garcı´a-Rı´o,Dı´azdeAtauri,Mayos,Monasterio, disorderedbreathingandhypertension.NEnglJMed. Biometrika.1994;81:515-526.
delCampo,Montserrat. 2000;342(19):1378-1384. 21. RedlineS,YenokyanG,GottliebDJ,etal.Ob-
Analysisandinterpretationofdata:Barbe´,Dura´n- 5. GottliebDJ,YenokyanG,NewmanAB,etal.Pro- structivesleepapnea-hypopneaandincidentstroke:
Cantolla,Sa´nchez-de-la-Torre,Martı´nez-Alonso, spectivestudyofobstructivesleepapneaandinci- theSleepHeartHealthStudy.AmJRespirCritCare
Barcelo´,Masa,Marı´n,Garcı´a-Rı´o,Tera´n,delaPen˜a, dentcoronaryheartdiseaseandheartfailure:theSleep Med.2010;182(2):269-277.
Monasterio,delCampo,Montserrat. Heart Health Study. Circulation. 2010;122(4): 22. Dura´n-CantollaJ,AizpuruF,Martı´nez-NullC,
Draftingofthemanuscript:Barbe´,Martı´nez-Alonso, 352-360. Barbe´-IllaF.Obstructivesleepapnea/hypopneaand
Chiner. 6. YaggiHK,ConcatoJ,KernanWN,LichtmanJH, systemichypertension.SleepMedRev.2009;13
Criticalrevisionofthemanuscriptforimportantin- BrassLM,MohseninV.Obstructivesleepapneaasa (5):323-331.
tellectualcontent:Barbe´,Dura´n-Cantolla,Sa´nchez- riskfactorforstrokeanddeath.NEnglJMed.2005; 23. GilesTL,LassersonTJ,SmithBJ,WhiteJ,Wright
de-la-Torre,Martı´nez-Alonso,Carmona,Barcelo´, 353(19):2034-2041. J,CatesCJ.Continuouspositiveairwayspressurefor
Chiner, Masa, Gonzalez, Marı´n, Garcı´a-Rı´o, 7. YoungT,FinnL,PeppardPE,etal.Sleepdisor- obstructivesleepapnoeainadults.CochraneData-
Dı´azdeAtauri,Tera´n,Mayos,delaPen˜a,Monasterio, deredbreathingandmortality:eighteen-yearfol- baseSystRev.2006;(1):CD001106.
delCampo,Montserrat. low-upoftheWisconsinSleepCohort.Sleep.2008; 24. McDaidC,Dure´eKH,GriffinSC,etal.Asystem-
Statisticalanalysis:Barbe´,Martı´nez-Alonso. 31(8):1071-1078. aticreviewofcontinuouspositiveairwaypressurefor
Obtainedfunding:Barbe´,Dura´n-Cantolla,Sa´nchez- 8. LavieP,HererP,PeledR,etal.Mortalityinsleep obstructivesleepapnoea-hypopnoeasyndrome.Sleep
de-la-Torre,Masa,Marı´n,delCampo,Montserrat. apneapatients:amultivariateanalysisofriskfactors. MedRev.2009;13(6):427-436.
Administrative,technical,ormaterialsupport:Barbe´, Sleep.1995;18(3):149-157. 25. AlajmiM,MulgrewAT,FoxJ,etal.Impactofcon-
Sa´nchez-de-la-Torre,Carmona,Barcelo´,delaPen˜a, 9. MontserratJM,FerrerM,HernandezL,etal.Ef- tinuouspositiveairwaypressuretherapyonbloodpres-
Monasterio. fectivenessofCPAPtreatmentindaytimefunctionin sure in patients with obstructive sleep apnea-
Studysupervision:Barbe´,Dura´n-Cantolla,Sa´nchez- sleepapneasyndrome:arandomizedcontrolledstudy hypopnea:ameta-analysisofrandomizedcontrolled
de-la-Torre,Chiner,Masa,Marı´n,Tera´n,Monasterio, withanoptimizedplacebo.AmJRespirCritCareMed. trials.Lung.2007;185(2):67-72.
delCampo,Montserrat. 2001;164(4):608-613. 26. HaentjensP,VanMeerhaegheA,MoscarielloA,
ConflictofInterestDisclosures:Allauthorshavecom- 10. BazzanoLA,KhanZ,ReynoldsK,HeJ.Effectof etal.Theimpactofcontinuouspositiveairwaypres-
pletedandsubmittedtheICMJEFormforDisclosure nocturnalnasalcontinuouspositiveairwaypressure sureonbloodpressureinpatientswithobstructivesleep
ofPotentialConflictsofInterestandnonewerere- on blood pressure in obstructive sleep apnea. apneasyndrome:evidencefromameta-analysisofpla-
ported. Hypertension.2007;50(2):417-423. cebo-controlledrandomizedtrials.ArchInternMed.
Funding/Support:ThisstudywasfundedbytheIn- 11. MarinJM,CarrizoSJ,VicenteE,AgustiAG.Long- 2007;167(8):757-764.
stitutodeSaludCarlosIII(PI04/0165)(FondodeIn- termcardiovascularoutcomesinmenwithobstruc- 27. MoL,HeQY.Effectoflong-termcontinuousposi-
vestigacionesSanitarios,MinisteriodeSanidadyCon- tivesleepapnoea-hypopnoeawithorwithouttreat- tiveairwaypressureventilationonbloodpressurein
sumo,Spain),SpanishRespiratorySociety(SEPAR) mentwithcontinuouspositiveairwaypressure:an patientswithobstructivesleepapneahypopneasyn-
(Barcelona),Resmed(BellaVista,Australia),Air observationalstudy.Lancet.2005;365(9464):1046- drome:ameta-analysisofclinicaltrials[inChinese].
Products–CarburosMetalicos(Barcelona),Respiron- 1053. ZhonghuaYiXueZaZhi.2007;87(17):1177-1180.
ics(Murrysville,Pennsylvania),andBreasMedical(Ma- 12. BuchnerNJ,SannerBM,BorgelJ,RumpLC.Con- 28. Barbe´F,Dura´n-CantollaJ,CapoteF,etal;Span-
drid,Spain). tinuouspositiveairwaypressuretreatmentofmildto ishSleepandBreathingGroup.Long-termeffectof
RoleoftheSponsors:Thefundingagencieshadno moderateobstructivesleepapneareducescardiovas- continuouspositiveairwaypressureinhypertensive
roleinthedesignandconductofthestudy;thecol- cularrisk.AmJRespirCritCareMed.2007;176 patientswithsleepapnea.AmJRespirCritCareMed.
lection,management,analysis,andinterpretationof (12):1274-1280. 2010;181(7):718-726.
thedata;orthepreparation,review,orapprovalof 13. Barbe´F,MayoralasLR,DuranJ,etal.Treatment 29. Dura´n-CantollaJ,AizpuruF,MontserratJM,etal;
themanuscript. withcontinuouspositiveairwaypressureisnoteffec- SpanishSleepandBreathingGroup.Continuousposi-
MembersoftheSpanishSleepandBreathingNet- tiveinpatientswithsleepapneabutnodaytimesleepi- tiveairwaypressureastreatmentforsystemichyper-
work:CoordinatorCentre,IRBLleida,Lleida:Marina ness:arandomized,controlledtrial.AnnInternMed. tensioninpeoplewithobstructivesleepapnoea:ran-
Lumbierres,SilviaGomez,CristinaEsquinas.Hospital 2001;134(11):1015-1023. domisedcontrolledtrial.BMJ.2010;341:c5991.
UniversitariodeÁlava,Vitoria:Ramo´nRubio,Ger- 14. RobinsonGV,SmithDM,LangfordBA,Davies 30. KohlerM,PepperellJC,CasadeiB,etal.CPAP
ma´ndelaTorre,CristinaMartinez-Null.HospitalVirgen RJ,StradlingJR.Continuouspositiveairwaypressure andmeasuresofcardiovascularriskinmaleswithOSAS.
delRocı´o,Sevilla:FranciscoCapote,AngelesSa´nchez- doesnotreducebloodpressureinnonsleepyhyper- EurRespirJ.2008;32(6):1488-1496.
Armengol.HospitalSantJoan,Alacant:MonicaLlom- tensiveOSApatients.EurRespirJ.2006;27(6): 31. PekerY,HednerJ,NorumJ,KraicziH,CarlsonJ.
bart.HospitalSanPedrodeAlca´ntaraHospital,Ca´- 1229-1235. Increasedincidenceofcardiovasculardiseaseinmiddle-
ceres:Fa´timaMorante,ManuelaRubio,JaimeCorral. 15. HednerJ,GroteL.Thelinkbetweensleepapnea agedmenwithobstructivesleepapnea:a7-year
HospitalMarquésdeValdecilla,Santander:M.A´nge- andcardiovasculardisease:timetotargetthenon- follow-up.AmJRespirCritCareMed.2002;166
lesMartinez.HospitalMiguelServet,Zaragoza:San- sleepysleepapneics?AmJRespirCritCareMed.2001; (2):159-165.
tiagoCarrizo.HospitalUniversitarioLaPaz-IdiPAZ,Ma- 163(1):5-6. 32. DohertyLS,KielyJL,SwanV,McNicholasWT.
drid:OlgaMediano,VanesaLores.HospitalGeneral 16. WheltonPK,AppelLJ,EspelandMA,etal;TONE Long-termeffectsofnasalcontinuouspositiveair-
Yagu¨e,Burgos:M.L.AlonsoA´lvarez.Hospitalde CollaborativeResearchGroup.Sodiumreductionand waypressuretherapyoncardiovascularoutcomesin
Bellvitge,Barcelona:NeusSalord.HospitalClinic,Bar- weightlossinthetreatmentofhypertensioninolder sleepapneasyndrome.Chest.2005;127(6):2076-
celona:LourdesHerna´ndez.CIBERes,Madrid:Neus persons:arandomizedcontrolledtrialofnonpharma- 2084.
Salord,CristinaEsquinas. cologicinterventionsintheelderly(TONE).JAMA. 33. MartiS,SampolG,Mun˜ozX,etal.Mortalityin
Online-OnlyMaterial:TheeAppendix,eFigures1and 1998;279(11):839-846. severesleepapnoea/hypopnoeasyndromepatients:
2,eTables1-7,andtheAuthorVideoIntervieware 17. MasaJF,Jime´nezA,Dura´nJ,etal.Alternative impact of treatment. Eur Respir J. 2002;20(6):
availableathttp://www.jama.com. methodsoftitratingcontinuouspositiveairwaypres- 1511-1518.
2168 JAMA,May23/30,2012—Vol307,No.20 ©2012AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://jama.jamanetwork.com/ by a Fudan University User on 05/11/2015
